Dr. Erika Hamilton spoke with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

In this retrospective cohort study of a large population in Belgium, researchers aimed to examine endometrial cancer risk in patients with breast cancer who received tamoxifen.

In the AXSANA/EUBREAST 3(R) study, researchers compared data about recurrence outcomes of more-invasive and less-invasive lymph node procedures.

TUESDAY, Dec. 16, 2025 (HealthDay News) – Giredestrant, a selective estrogen receptor antagonist and degrader given as an adjuvant therapy, shows significant improvement in invasive disease-free ...

Please provide your email address to receive an email when new articles are posted on . San Antonio Breast Cancer Symposium metastatic breast cancer updates range from anti-estrogen therapies to ...

The San Antonio Breast Cancer Symposium fosters collaboration among experts, enhancing research and treatment strategies for breast cancer's complex landscape. Justin Drake, PhD: It's an amazing ...

WEDNESDAY, Dec. 17, 2025 (HealthDay News) -- Risk-based screening, including genetic testing, is noninferior to annual screening for detecting stage ≥IIB cancers and does not reduce biopsy rates ...

Giredestrant significantly improves invasive disease-free survival in ER+/HER2– early breast cancer, reducing recurrence or death risk by 30% compared to standard endocrine therapy. Tukysa, combined ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — In this video, Erica L. Mayer, MD, MPH, discusses highlights from San Antonio Breast Cancer ...

SAN ANTONIO -- Menopausal hormone therapy (MHT) did not increase breast cancer risk in women with BRCA mutations, according to a study reported here. In fact, women who used estrogen-only MHT had a ...

A long-delayed homicide case against a former San Leandro police officer may be coming to an end. The Alameda County District Attorney has told the family of Steven Taylor that she intends to drop the ...

At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen-receptor degrader (SERD) giredestrant significantly reduced recurrence ...